Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from CStone Pharmaceuticals ( (HK:2616) ) is now available.
CStone Pharmaceuticals announced that the Stock Exchange of Hong Kong has publicly criticized Mr. Sun Hongbin, an independent non-executive director of the company, for conduct violations during his tenure at New Century Healthcare. The company’s board has assessed the situation and determined that the criticism does not impact CStone’s operations or business, but they will continue to monitor Mr. Sun’s eligibility to serve in his current role.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative immuno-oncology and precision medicine therapies. The company operates in the pharmaceutical industry, with a market focus on developing treatments for cancer and other serious diseases.
Average Trading Volume: 11,209,293
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.29B
For an in-depth examination of 2616 stock, go to TipRanks’ Overview page.